Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 6/20 | 0.54 |
| ▸ | LMNA | P02545 | 5/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.54 |
| ▸ | HTR1A | P08908 | 2/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.54 |
| ▸ | DRD2 | P14416 | 2/20 | 0.54 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1151794 | 1.00 | OPRD1 (0.54) | OPRD1LMNAHIF1ANPSR1CYP3A4 | |
| SCHEMBL1152562 | 0.85 | LMNA (0.56) | OPRD1LMNAHIF1ANPSR1CYP3A4 | |
| SCHEMBL1152565 | 0.85 | LMNA (0.56) | OPRD1LMNAHIF1ANPSR1CYP3A4 | |
| SCHEMBL1152689 | 0.82 | LMNA (0.55) | OPRD1LMNAHIF1ANPSR1CYP3A4 | |
| SCHEMBL1152693 | 0.82 | LMNA (0.55) | OPRD1LMNAHIF1ANPSR1CYP3A4 | |
| SCHEMBL1152757 | 0.81 | LMNA (0.81) | OPRD1LMNAHIF1ANPSR1CYP3A4 | |
| SCHEMBL1152760 | 0.81 | LMNA (0.81) | OPRD1LMNAHIF1ANPSR1CYP3A4 | |
| Hydrochloric Acid SCHEMBL7271730 | 0.74 | KMT2A (0.62) | OPRD1LMNANPSR1GAACYP2D6 | |
| SCHEMBL1151945 | 0.74 | LMNA (0.52) | OPRD1LMNAHIF1ANPSR1CYP3A4 | |
| SCHEMBL1151942 | 0.74 | LMNA (0.52) | OPRD1LMNAHIF1ANPSR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2013-10-31 | — | — | US | disclosed |
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
| US-4792553-A | TREATMENT OF CARDIOVASCULAR AND CEREBROVASCULAR DISORDERS | TERUMO KABUSHIKI KAISHA (JP) | 1988-12-20 | — | — | US | disclosed |
| EP-0232205-A2 | Diene derivatives and vasodilators containing the same | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION (JP) | 1987-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | OPRD1 4466/4885LMNA 156/4885HIF1A 1389/4885 |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | OPRD1 4466/4885LMNA 156/4885HIF1A 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.